Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
FiercePharma11h
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
Novo Nordisk Reports Strong Growth in 2024
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...
U.S. News & World Report2d
Novo Nordisk Narrows 2024 Guidance Range, Q3 in Line With Expectations
COPENHAGEN (Reuters) -Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit ...
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...